Literature DB >> 32103695

Pharmacotherapeutic management of co-morbid alcohol and opioid use.

Lauren E Hood1, Jonna M Leyrer-Jackson1, M Foster Olive1.   

Abstract

Opioid use disorder (OUD) and alcohol use disorder (AUD) are two highly prevalent substance-related disorders worldwide. Co-use of the substances is also quite prevalent, yet there are no pharmacological treatment approaches specifically designed to treat co-morbid OUD and AUD. Here, the authors critically summarize OUD, AUD and opioid/alcohol co-use and their current pharmacotherapies for treatment. They also review the mechanisms of action of opioids and alcohol within the brain reward circuitry and discuss potential combined mechanisms of action and resulting neuroadaptations. Pharmacotherapies that aim to treat AUD or OUD that may be beneficial in the treatment of co-use are also highlighted. Preclinical models assessing alcohol and opioid co-use remain sparse. Lasting neuroadaptations in brain reward circuits caused by co-use of alcohol and opioids remains largely understudied. In order to fully understand the neurobiological underpinnings of alcohol and opioid co-use and develop efficacious pharmacotherapies, the preclinical field must expand its current experimental paradigms of 'single drug' use to encompass polysubstance use. Such studies will provide insights on the neural alterations induced by opioid and alcohol co-use, and may help develop novel pharmacotherapies for individuals with co-occurring alcohol and opioid use disorders.

Entities:  

Keywords:  AUD; Alcohol; OUD; co-morbidity; co-use; opiate; opioid; pharmacotherapies

Mesh:

Substances:

Year:  2020        PMID: 32103695      PMCID: PMC7239727          DOI: 10.1080/14656566.2020.1732349

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  182 in total

Review 1.  NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity.

Authors:  J Mao
Journal:  Brain Res Brain Res Rev       Date:  1999-11

2.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Authors:  R Spanagel; A Herz; T S Shippenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

3.  Does Acamprosate Really Produce its Anti-Relapse Effects via Calcium? No Support from the PREDICT Study in Human Alcoholics.

Authors:  Karl Mann; Sabine Hoffmann; Cornelius R Pawlak
Journal:  Neuropsychopharmacology       Date:  2016-02       Impact factor: 7.853

Review 4.  Opioids: cellular mechanisms of tolerance and physical dependence.

Authors:  Chris P Bailey; Mark Connor
Journal:  Curr Opin Pharmacol       Date:  2005-02       Impact factor: 5.547

5.  Rewarding morphine-induced synaptic function of delta-opioid receptors on central glutamate synapses.

Authors:  Bihua Bie; Wei Zhu; Zhizhong Z Pan
Journal:  J Pharmacol Exp Ther       Date:  2009-01-23       Impact factor: 4.030

6.  Acamprosate, alcoholism, and abstinence.

Authors:  Barbara J Mason
Journal:  J Clin Psychiatry       Date:  2015-02       Impact factor: 4.384

7.  mu-Opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons.

Authors:  G Martin; Z Nie; G R Siggins
Journal:  J Neurosci       Date:  1997-01-01       Impact factor: 6.167

8.  Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: an in vivo microdialysis study.

Authors:  M J Cano-Cebrián; T Zornoza-Sabina; C Guerri; A Polache; L Granero
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-23       Impact factor: 3.000

9.  Association between DRD2, 5-HTTLPR, and ALDH2 genes and specific personality traits in alcohol- and opiate-dependent patients.

Authors:  Tzu-Yun Wang; Sheng-Yu Lee; Shiou-Lan Chen; San-Yuan Huang; Yun-Hsuan Chang; Nian-Sheng Tzeng; Chen-Lin Wang; I Hui Lee; Tzung Lieh Yeh; Yen Kuang Yang; Ru-Band Lu
Journal:  Behav Brain Res       Date:  2013-05-16       Impact factor: 3.332

10.  Sequential cocaine-alcohol self-administration produces adaptations in rat nucleus accumbens core glutamate homeostasis that are distinct from those produced by cocaine self-administration alone.

Authors:  Bethany A Stennett; Yasmin Padovan-Hernandez; Lori A Knackstedt
Journal:  Neuropsychopharmacology       Date:  2019-07-02       Impact factor: 8.294

View more
  3 in total

1.  Elevated customary alcohol consumption attenuates opioid effects.

Authors:  Monique M Cherrier; Danny D Shen; Laura Shireman; Andrew J Saxon; Tracy Simpson; Alex Men; Preetma Kooner; Gregory W Terman
Journal:  Pharmacol Biochem Behav       Date:  2021-11-04       Impact factor: 3.533

2.  Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

Authors:  John D Roache; Martina Pavlicova; Aimee Campbell; Tse-Hwei Choo; Michelle Peavy; Andrea S Kermack; Edward V Nunes; John Rotrosen
Journal:  Alcohol Clin Exp Res       Date:  2021-11-23       Impact factor: 3.455

3.  Positive associations between cannabis and alcohol use polygenic risk scores and phenotypic opioid misuse among African-Americans.

Authors:  Jill A Rabinowitz; Jin Jin; Sally I-Chun Kuo; Adrian I Campos; Miguel E Rentería; Andrew S Huhn; Johannes Thrul; Beth A Reboussin; Kelly Benke; Benjamin Domingue; Nicholas S Ialongo; Brion S Maher; Darlene Kertes; Vanessa Troiani; George Uhl
Journal:  PLoS One       Date:  2022-04-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.